{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T00:15:23Z","timestamp":1717287323920},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"DOI":"10.7759\/cureus.61504","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T17:47:49Z","timestamp":1717264069000},"source":"Crossref","is-referenced-by-count":0,"title":["Immunophenotypic Profile and Measurable Residual Disease Monitoring in Multiple Myeloma: A Prospective Study From a Tertiary Care Centre in Southern India"],"prefix":"10.7759","author":[{"given":"Pandurangan","family":"Sathya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smita","family":"Kayal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdoul","family":"Hamide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakhee","family":"Kar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01127.x","article-title":"Multiple myeloma--an update on diagnosis and treatment","volume":"81","author":"Caers J","year":"2008","unstructured":"Caers J, Vande broek I, De Raeve H, et al.. Multiple myeloma--an update on diagnosis and treatment. Eur J Haematol. 2008, 81:329-43. 10.1111\/j.1600-0609.2008.01127.x","journal-title":"Eur J Haematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated the criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar SV","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, et al.. International Myeloma Working Group updated the criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014, 15:538-48. 10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar SK","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, et al.. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008, 111:2516-20. 10.1182\/blood-2007-10-116129","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal M","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, et al.. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996, 335:91-7. 10.1056\/NEJM199607113350204","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva B","year":"2008","unstructured":"Paiva B, Vidriales MB, Cerver\u00f3 J, et al.. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008, 112:4017-23. 10.1182\/blood-2008-05-159624","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.90","article-title":"Current applications of multiparameter flow cytometry in plasma cell disorders","volume":"7","author":"Jelinek T","year":"2017","unstructured":"Jelinek T, Bezdekova R, Zatopkova M, et al.. Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer J. 2017, 7:e617. 10.1038\/bcj.2017.90","journal-title":"Blood Cancer J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20512","article-title":"Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders","volume":"78","author":"Paiva B","year":"2010","unstructured":"Paiva B, Almeida J, P\u00e9rez-Andr\u00e9s M, et al.. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom. 2010, 78:239-52. 10.1002\/cyto.b.20512","journal-title":"Cytometry B Clin Cytom"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.5.1853","article-title":"Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome","volume":"99","author":"San Miguel JF","year":"2002","unstructured":"San Miguel JF, Almeida J, Mateo G, et al.. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood. 2002, 99:1853-6. 10.1182\/blood.v99.5.1853","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero J","year":"2017","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, et al.. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017, 31:2094-103. 10.1038\/leu.2017.29","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000331","article-title":"Utility of flow cytometry studies in the management of patients with multiple myeloma","volume":"28","author":"Paiva B","year":"2016","unstructured":"Paiva B, Merino J, San Miguel JF. Utility of flow cytometry studies in the management of patients with multiple myeloma. Curr Opin Oncol. 2016, 28:511-7. 10.1097\/CCO.0000000000000331","journal-title":"Curr Opin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00699","article-title":"Minimal residual disease assessment within the bone marrow of multiple myeloma: a review of caveats, clinical significance and future perspectives","volume":"9","author":"Romano A","year":"2019","unstructured":"Romano A, Palumbo GA, Parrinello NL, Conticello C, Martello M, Terragna C. Minimal residual disease assessment within the bone marrow of multiple myeloma: a review of caveats, clinical significance and future perspectives. Front Oncol. 2019, 9:699. 10.3389\/fonc.2019.00699","journal-title":"Front Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_159009","article-title":"Updated diagnostic criteria and staging system for multiple myeloma","volume":"35","author":"Rajkumar SV","year":"2016","unstructured":"Rajkumar SV. Updated diagnostic criteria and staging system for multiple myeloma. Am Soc Clin Oncol Educ Book. 2016, 35:e418-23. 10.1200\/EDBK_159009","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12558-013-0294-5","article-title":"A review of 74 patients with newly diagnosed multiple myeloma at a tertiary referral hospital in Nairobi, Kenya","volume":"6","author":"Kiraka G","year":"2014","unstructured":"Kiraka G, Etabale M, Riyat M. A review of 74 patients with newly diagnosed multiple myeloma at a tertiary referral hospital in Nairobi, Kenya. J Afr Cancer. 2014, 6:70-4. 10.1007\/s12558-013-0294-5","journal-title":"J Afr Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle RA","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, et al.. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003, 78:21-33. 10.4065\/78.1.21","journal-title":"Mayo Clin Proc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003","volume":"25","author":"Kristinsson SY","year":"2007","unstructured":"Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bj\u00f6rkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007, 25:1993-9. 10.1200\/JCO.2006.09.0100","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1179\/1607845415Y.0000000010","article-title":"The prognostic impact of multiparameter flow cytometry immunophenotyping and cytogenetic aberrancies in patients with multiple myeloma","volume":"21","author":"Guo J","year":"2016","unstructured":"Guo J, Su J, He Q, et al.. The prognostic impact of multiparameter flow cytometry immunophenotyping and cytogenetic aberrancies in patients with multiple myeloma. Hematology. 2016, 21:152-61. 10.1179\/1607845415Y.0000000010","journal-title":"Hematology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.5920","article-title":"Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib","volume":"13","author":"Iriyama N","year":"2017","unstructured":"Iriyama N, Miura K, Hatta Y, et al.. Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib. Oncol Lett. 2017, 13:3803-8. 10.3892\/ol.2017.5920","journal-title":"Oncol Lett"},{"key":"ref18","article-title":"The phenotype of normal, reactive and malignant plasma cells. Identification of\" many and multiple myelomas\" and of new targets for myeloma therapy","volume":"1","author":"Bataille R","year":"2006","unstructured":"Bataille R, J\u00e9go G, Robillard N, et al.. The phenotype of normal, reactive and malignant plasma cells. Identification of\" many and multiple myelomas\" and of new targets for myeloma therapy. Haematologica. 2006, 1:1234-40.","journal-title":"Haematologica"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4120","article-title":"Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA\/GEM cooperative study groups on patients uniformly treated with high-dose therapy","volume":"26","author":"Mateo G","year":"2008","unstructured":"Mateo G, Montalb\u00e1n MA, Vidriales MB, et al.. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA\/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol. 2008, 26:2737-44. 10.1200\/JCO.2007.15.4120","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5812\/ijcm.5350","article-title":"Plasma cell immunophenotyping improve prognostic stratification of multiple myeloma patients","volume":"11","author":"Meddour Y","year":"2018","unstructured":"Meddour Y, Rahali MC, Belakehal SE, Benfenatki N, Zohra Ardjoune F, Chaib S, Djidjik R. Plasma cell immunophenotyping improve prognostic stratification of multiple myeloma patients. Int J Cancer Manag. 2018, 11:e5350. 10.5812\/ijcm.5350","journal-title":"Int J Cancer Manag"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05849.x","article-title":"Lack of CD27 in myeloma delineates different presentation and outcome","volume":"132","author":"Moreau P","year":"2006","unstructured":"Moreau P, Robillard N, J\u00e9go G, et al.. Lack of CD27 in myeloma delineates different presentation and outcome. Br J Haematol. 2006, 132:168-70. 10.1111\/j.1365-2141.2005.05849.x","journal-title":"Br J Haematol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403823","article-title":"CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations","volume":"19","author":"Kumar S","year":"2005","unstructured":"Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia. 2005, 19:1466-70. 10.1038\/sj.leu.2403823","journal-title":"Leukemia"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.03.003","article-title":"The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma","volume":"44","author":"Gonsalves WI","year":"2016","unstructured":"Gonsalves WI, Timm MM, Rajkumar SV, et al.. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leuk Res. 2016, 44:32-9. 10.1016\/j.leukres.2016.03.003","journal-title":"Leuk Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.42","article-title":"Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients","volume":"26","author":"Paiva B","year":"2012","unstructured":"Paiva B, Guti\u00e9rrez NC, Chen X, et al.. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia. 2012, 26:1862-9. 10.1038\/leu.2012.42","journal-title":"Leukemia"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0297","article-title":"Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation","volume":"100","author":"Rawstron AC","year":"2002","unstructured":"Rawstron AC, Davies FE, DasGupta R, et al.. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood. 2002, 100:3095-100. 10.1182\/blood-2001-12-0297","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-029355","article-title":"CD200 is a new prognostic factor in multiple myeloma","volume":"108","author":"Moreaux J","year":"2006","unstructured":"Moreaux J, Hose D, Reme T, et al.. CD200 is a new prognostic factor in multiple myeloma. Blood. 2006, 108:4194-7. 10.1182\/blood-2006-06-029355","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (Velcade\u2122) in the treatment of multiple myeloma","volume":"2","author":"Field-Smith A","year":"2006","unstructured":"Field-Smith A, Morgan GJ, Davies FE. Bortezomib (Velcade\u2122) in the treatment of multiple myeloma. Ther Clin Risk Manag. 2006, 2:271-9. 10.2147\/tcrm.2006.2.3.271","journal-title":"Ther Clin Risk Manag"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis","volume":"20","author":"Avet-Loiseau H","year":"2020","unstructured":"Avet-Loiseau H, Ludwig H, Landgren O, et al.. Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis. Clin Lymphoma Myeloma Leuk. 2020, 20:e30-7. 10.1016\/j.clml.2019.09.622","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez J","year":"2014","unstructured":"Martinez-Lopez J, Lahuerta JJ, Pepin F, et al.. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014, 123:3073-9. 10.1182\/blood-2014-01-550020","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma","volume":"119","author":"Paiva B","year":"2012","unstructured":"Paiva B, Guti\u00e9rrez NC, Rosi\u00f1ol L, et al.. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012, 119:687-91. 10.1182\/blood-2011-07-370460","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/248470-immunophenotypic-profile-and-measurable-residual-disease-monitoring-in-multiple-myeloma-a-prospective-study-from-a-tertiary-care-centre-in-southern-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T17:47:52Z","timestamp":1717264072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/248470-immunophenotypic-profile-and-measurable-residual-disease-monitoring-in-multiple-myeloma-a-prospective-study-from-a-tertiary-care-centre-in-southern-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,1]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.61504","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,1]]}}}